Eli Lilly’s weight-loss pill wins backing in Europe
The recommendation sends the once-daily tablet to the European Commission after late-stage trials showed about 11% average weight loss over 72 weeks.
8 Articles
8 Articles
In clinical trials, Eli Lilly's orforlipron offered weight loss of up to 10%. The EMA recommended its approval against obesity and type 2 diabetes. The post Green light in Europe for a second anti-obesity pill appeared first on in.gr.
A committee of the EU authority recommended the approval of the drug. Thus, the pill Wegovy of the Danish rival Novo Nordisk received competition on the European market.
Eli Lilly’s weight-loss pill wins backing in Europe
Oct 16 (Reuters) - The European Medicines Agency's committee on Friday recommended approval of Eli Lilly's weight-loss pill Foundayo, paving the way for a second oral weight-loss drug to win backing in the region after Novo Nordisk's We...
The European Medicines Agency EMA recommends approval for the GLP1 analogue Foundayo (orforgliprone) as a treatment for type 2 diabetes and obesity.
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
